CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.78B, above the global median of $1.18B
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 77.2%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.78BUSDvs all stocks (USD)
Revenue (TTM)
303.23MUSDvs all stocks (USD)
Profit Margin
-83.00%vs Biotechnology peers
Beta
1.63xvs all stocks
52-Week Change
86.68%vs all stocks
Market Capitalization
1.78BUSDvs all stocks (USD)
Enterprise Value
1.36BUSDvs all stocks (USD)
Forward P/E
-4.29xvs Biotechnology peers
Price to Sales (TTM)
5.95xvs Biotechnology peers
Price to Book (MRQ)
1.84xvs Biotechnology peers
Enterprise to Revenue
4.50xvs Biotechnology peers
Enterprise to EBITDA
-5.09xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Profit Margin
-83.00%vs Biotechnology peers
Operating Margin
30.75%vs Biotechnology peers
Return on Assets (TTM)
-14.51%vs Biotechnology peers
Return on Equity (TTM)
-26.08%vs Biotechnology peers
Revenue (TTM)
303.23MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.04USDUpdated Sep 28, 2026Quarterly Revenue Growth
19582.50%vs Biotechnology peers
Gross Profit (TTM)
-180.08MUSDvs all stocks (USD)
EBITDA (TTM)
-267.96MUSDvs all stocks (USD)
Net Income (TTM)
-251.68MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
23075.07%vs Biotechnology peers
Operating Cash Flow (TTM)
-202.51MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-38.89MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
66.52MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
26.00KUSDFY2025 · Dec 31, 2025Gross Profit
66.49MUSDFY2025 · Dec 31, 2025Operating Income
-479.51MUSDvs all stocks (USD)
Pre-tax Income
-437.77MUSDFY2025 · Dec 31, 2025Income Tax Expense
217.00KUSDFY2025 · Dec 31, 2025Net Income
-437.99MUSDFY2025 · Dec 31, 2025EBIT
-479.51MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-469.74MUSDFY2025 · Dec 31, 2025Research & Development
455.97MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
92.07MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-2.04MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
40.24MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.16USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.16USDFY2025 · Dec 31, 2025Basic Shares Outstanding
138.52MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
138.52MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-437.99MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-392.09MUSDFY2025 · Dec 31, 2025Free Cash Flow
-396.67MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
241.07MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-437.99MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.68MUSDFY2025 · Dec 31, 2025Stock-based Compensation
49.07MUSDFY2025 · Dec 31, 2025Other Non-cash Items
156.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
5.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.01MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.58MUSDFY2025 · Dec 31, 2025Purchase of Investments
-886.33MUSDFY2025 · Dec 31, 2025Sale of Investments
1.20BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
310.37MUSDFY2025 · Dec 31, 2025Other Financing Charges
-361.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-361.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
169.19MSharesUpdated Sep 28, 2026Float Shares
129.80MSharesUpdated Sep 28, 2026Shares Short
19.66MSharesUpdated Sep 28, 2026Short Ratio
9.70daysvs all stocks
Short % of Shares Outstanding
11.76%vs all stocks
% Held by Insiders
6.57%vs all stocks
% Held by Institutions
84.22%vs all stocks
Total Cash (MRQ)
532.73MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.15USDUpdated Sep 28, 2026Total Debt (MRQ)
93.27MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0949xvs Biotechnology peers
Current Ratio (MRQ)
6.04xvs Biotechnology peers
Book Value per Share (MRQ)
5.81USDUpdated Sep 28, 2026Total Assets
1.00BUSDvs all stocks (USD)
Total Current Assets
514.08MUSDFY2025 · Dec 31, 2025Total Liabilities
237.55MUSDFY2025 · Dec 31, 2025Total Non-current Assets
488.74MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
144.73MUSDFY2025 · Dec 31, 2025Total Current Liabilities
92.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
232.19MUSDFY2025 · Dec 31, 2025Other Short-term Investments
234.83MUSDFY2025 · Dec 31, 2025Accounts Payable
9.80MUSDFY2025 · Dec 31, 2025Short-term Debt
8.80MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Long-term Debt
89.05MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
55.68MUSDFY2025 · Dec 31, 2025Common Stock (Book)
14.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.20BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
765.28MUSDvs all stocks (USD)
52-Week Low
4.82USDUpdated Sep 28, 202652-Week High
11.94USDUpdated Sep 28, 202652-Week Change
86.68%vs all stocks
Beta
1.63xvs all stocks
50-Day MA
9.98USDUpdated Sep 28, 2026200-Day MA
8.92USDUpdated Sep 28, 2026Avg 10-Day Volume
2.32MSharesUpdated Sep 28, 2026Avg 30-Day Volume
2.09MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.77USDUpdated Sep 28, 2026Other Income / Expense
1.50MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 77.2%)Significant
Gross margin: 1.00Industry median: 0.77Industry P95: 0.99Peers compared: 193
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: -0.83
Financial Health
Altman Z-Score 1.81: grey zoneSignificant
Altman Z-Score: 1.81
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.78B, above the global median of $1.18BNotable
Market cap (USD): 1,778,459,718Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jafron Biomedical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xeris Biopharma Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Septarna Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zenas BioPharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Novavax Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Iovance Biotherapeutics, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
OmniAb, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity